Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Hypoglycemic Agents/adverse effects"'
Publikováno v:
Diabetes Research and Clinical Practice. 200
AIMS: To explore determinants of excessive weight gain after initiation of insulin therapy in type 2 diabetes mellitus (T2DM), in particular variables identified in the pre-insulin phase.METHODS: We performed a retrospective observational interventio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3743d1e9e90b8d0f96d2703ff85fb73d
https://doi.org/10.1016/j.diabres.2023.110719
https://doi.org/10.1016/j.diabres.2023.110719
Publikováno v:
Revista Portuguesa de Farmacoterapia, Vol 11, Iss 2-3 (2019)
Introduction: Our objective was to investigate associations between oral antidiabetics and adverse drug reactions through disproportionality analysis in the Portuguese Pharmacovigilance System database. Methods: Spontaneous reports of adverse drug
Externí odkaz:
https://doaj.org/article/431da7cb3d244ce6917fda05b970884e
Autor:
Kristian Løkke Funck, Lasse Bjerg, Anders Aasted Isaksen, Annelli Sandbæk, Erik Lerkevang Grove
Publikováno v:
Funck, K L, Bjerg, L, Isaksen, A A, Sandbæk, A & Grove, E L 2022, ' Gender disparities in time-to-initiation of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease : a Danish nationwide cohort study ', Cardiovascular Diabetology, vol. 21, 279 . https://doi.org/10.1186/s12933-022-01713-3
Background We aimed to examine the impact of gender and specific type of cardiovascular disease (CVD) diagnosis (ischemic heart disease [IHD], heart failure, peripheral artery disease [PAD] or stroke) on time-to-initiation of either a sodium glucose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccff5a1773d5ceae3e9720f7132639a5
https://pure.au.dk/portal/da/publications/gender-disparities-in-timetoinitiation-of-cardioprotective-glucoselowering-drugs-in-patients-with-type-2-diabetes-and-cardiovascular-disease(138e45e3-ec23-4824-a09d-aaf0c64bf476).html
https://pure.au.dk/portal/da/publications/gender-disparities-in-timetoinitiation-of-cardioprotective-glucoselowering-drugs-in-patients-with-type-2-diabetes-and-cardiovascular-disease(138e45e3-ec23-4824-a09d-aaf0c64bf476).html
Autor:
Molveau, Joséphine, Rabasa-Lhoret, Rémi, Myette-Côté, Étienne, Messier, Virginie, Suppère, Corinne, J Potter, Kathryn, Heyman, Elsa, Tagougui, Sémah
Publikováno v:
Frontiers in Endocrinology
Frontiers in Endocrinology, 2022, Frontiers in Endocrinology, 13, pp.953879. ⟨10.3389/fendo.2022.953879⟩
Frontiers in Endocrinology, 2022, Frontiers in Endocrinology, 13, pp.953879. ⟨10.3389/fendo.2022.953879⟩
ObjectiveStudies investigating strategies to limit the risk of nocturnal hypoglycemia associated with physical activity (PA) are scarce and have been conducted in standardized, controlled conditions in people with type 1 diabetes (T1D). This study so
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a66c844970ee38e48f738d981f924fb
http://hdl.handle.net/20.500.12210/79296
http://hdl.handle.net/20.500.12210/79296
Autor:
Katarzyna Nabrdalik, Karolina Skonieczna-Żydecka, Krzysztof Irlik, Mirela Hendel, Hanna Kwiendacz, Igor Łoniewski, Kornelia Januszkiewicz, Janusz Gumprecht, Gregory Y. H. Lip
Publikováno v:
Nabrdalik, K, Skonieczna-Żydecka, K, Irlik, K, Hendel, M, Kwiendacz, H, Łoniewski, I, Januszkiewicz, K, Gumprecht, J & Lip, G Y H 2022, ' Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus : A systematic review, meta-analysis and meta-regression of randomized controlled trials ', Frontiers in Endocrinology, vol. 13, 975912 . https://doi.org/10.3389/fendo.2022.975912
IntroductionMetformin is the first choice drug in the treatment of type 2 diabetes mellitus but its administration may be linked to gastrointestinal adverse events limiting its use.ObjectivesThe objective of this systematic review and meta-analysis w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8111c19d299579df5560c9fb6516f817
Autor:
Yi-Hsin Chan, Tze-Fan Chao, Shao-Wei Chen, Hsin-Fu Lee, Pei-Ru Li, Wei-Min Chen, Yung-Hsin Yeh, Chi-Tai Kuo, Lai-Chu See, Gregory Y. H. Lip
Publikováno v:
Chan, Y-H, Chao, T-F, Chen, S-W, Lee, H-F, Li, P-R, Chen, W-M, Yeh, Y-H, Kuo, C-T, See, L-C & Lip, G Y H 2022, ' The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors : a nationwide cohort study ', Cardiovascular Diabetology, vol. 21, no. 1, 118 . https://doi.org/10.1186/s12933-022-01549-x
Background Although a few meta-analyses were conducted to compare the risk of incident atrial fibrillation (AF) between sodium-glucose cotransporter-2 inhibitor (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RA), and other anti-hyperglycem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30a2658ea9d5bfd457223ac85a27e8ca
https://vbn.aau.dk/ws/files/475116687/Chan_et_al._2022_._The_risk_of_incident_atrial_fibrillation_in_patients_with_type_2_diabetes_treated_with_sodium_glucose_cotransporter_2_inhibitors_glucagon_like_peptide_1_receptor_agonists_and_dipeptidyl_peptidase_4_inhibitors.pdf
https://vbn.aau.dk/ws/files/475116687/Chan_et_al._2022_._The_risk_of_incident_atrial_fibrillation_in_patients_with_type_2_diabetes_treated_with_sodium_glucose_cotransporter_2_inhibitors_glucagon_like_peptide_1_receptor_agonists_and_dipeptidyl_peptidase_4_inhibitors.pdf
Autor:
Albert C.M. Ong, Ron T. Gansevoort
Publikováno v:
Kidney Int
Kidney International, 100(3), 513-515. ELSEVIER SCIENCE INC
Kidney International, 100(3), 513-515. ELSEVIER SCIENCE INC
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by growth of kidney cysts and glomerular filtration rate (GFR) decline. Metformin was found to impact cystogenesis in preclinical models of polycystic disease, is generally conside
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bee8533643b06bff9b95e40fafd3c1d7
https://doi.org/10.1016/j.kint.2021.07.021
https://doi.org/10.1016/j.kint.2021.07.021
Autor:
Stultiens, Johanna M. G., Top, Wiebe M. C., Kimenai, Dorien M., Lehert, Philippe, Bekers, Otto, Stehouwer, Coen D. A., Kooy, Adriaan, Meex, Steven J. R.
Publikováno v:
Cardiovascular Diabetology, 21(1):49. BioMed Central Ltd
Cardiovascular Diabetology, 21(1):49. BioMed Central Ltd.
Stultiens, J M G, Top, W M C, Kimenai, D M, Lehert, P, Bekers, O, Stehouwer, C D A, Kooy, A & Meex, S J R 2022, ' Metformin and high-sensitivity cardiac troponin I and T trajectories in type 2 diabetes patients: a post-hoc analysis of a randomized controlled trial ', Cardiovascular diabetology, vol. 21, no. 1 . https://doi.org/10.1186/s12933-022-01482-z
Cardiovascular Diabetology, 21(1):49. BioMed Central Ltd.
Stultiens, J M G, Top, W M C, Kimenai, D M, Lehert, P, Bekers, O, Stehouwer, C D A, Kooy, A & Meex, S J R 2022, ' Metformin and high-sensitivity cardiac troponin I and T trajectories in type 2 diabetes patients: a post-hoc analysis of a randomized controlled trial ', Cardiovascular diabetology, vol. 21, no. 1 . https://doi.org/10.1186/s12933-022-01482-z
Background Metformin has favorable effects on cardiovascular outcomes in both newly onset and advanced type 2 diabetes, as previously reported findings from the UK Prospective Diabetes Study and the HOME trial have demonstrated. Patients with type 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::303d2212d11a1a7168f44b36006c8f0d
https://cris.maastrichtuniversity.nl/en/publications/4ed03dc1-da2f-4a03-a4f2-23e73a90e755
https://cris.maastrichtuniversity.nl/en/publications/4ed03dc1-da2f-4a03-a4f2-23e73a90e755
Autor:
Nazanin Abolhassani, Ursula Winterfeld, Yusuf C Kaplan, Cécile Jaques, Beatrice Minder Wyssmann, Cinzia Del Giovane, Alice Panchaud
Publikováno v:
Abolhassani, Nazanin; Winterfeld, Ursula; Kaplan, Yusuf C; Jaques, Cécile; Minder Wyssmann, Beatrice; Del Giovane, Cinzia; Panchaud, Alice (2023). Major malformations risk following early pregnancy exposure to metformin: a systematic review and meta-analysis. BMJ open diabetes research & care, 11(1), e00291. BMJ Publishing Group 10.1136/bmjdrc-2022-002919
BMJ open diabetes research & care, vol. 11, no. 1, pp. e002919
BMJ open diabetes research & care, vol. 11, no. 1, pp. e002919
Metformin is considered as first-line treatment for type 2 diabetes and an effective treatment for polycystic ovary syndrome (PCOS). However, evidence regarding its safety in pregnancy is limited. We conducted a systematic review and meta-analysis of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57d023ea441655e91c90e8e9fb44fbcf
https://doi.org/10.1136/bmjdrc-2022-002919
https://doi.org/10.1136/bmjdrc-2022-002919
Publikováno v:
Primary care diabetes, vol. 13, no. 3, pp. 233-241
Aims We aimed to assess the health status and quality of life (QoL) of patients with diabetes and explore the associated factors in a French-speaking region of Switzerland. Methods This cross-sectional study analyzed self-reported data from 585 patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba8c0f1390303d9e72d368530fbfe61b
https://doi.org/10.1016/j.pcd.2018.11.016
https://doi.org/10.1016/j.pcd.2018.11.016